Evidence map›Paper›PMID 34637745›Full record

ArticleCancer cell2021

Redirecting tumor macrophage activity to fight cancer: Make room for the next era of anti-cancer drugs.

Ferdinando Pucci, Lisa M Coussens

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Ferdinando PucciDepartment of Otolaryngology, Head, and Neck Surgery, Oregon Health and Science University, 2720 South Moody Avenue, Mail Code: KR-CDCB, Portland, OR 97201, USA; Department of Cell, Developmental, and Cancer Biology, Oregon Health and Science University, 2720 South Moody Avenue, Mail Code: KR-CDCB, Portland, OR 97201, USA; Knight Cancer Institute, Oregon Health and Science University, 2720 South Moody Avenue, Mail Code: KR-CDCB, Portland, OR 97201, USA. Electronic address: pucci@ohsu.edu.
Lisa M CoussensDepartment of Cell, Developmental, and Cancer Biology, Oregon Health and Science University, 2720 South Moody Avenue, Mail Code: KR-CDCB, Portland, OR 97201, USA; Knight Cancer Institute, Oregon Health and Science University, 2720 South Moody Avenue, Mail Code: KR-CDCB, Portland, OR 97201, USA. Electronic address: coussenl@ohsu.edu.

Funding

Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5M
NCI NIH HHS P30 CA069533
6 · The paper itself

Abstract

Functionally significant proteins expressed by tumor macrophages have emerged as promising anti-cancer targets. In this issue of Cancer Cell, Sun et al. identify two FDA-approved agents that together safely reprogram tumor macrophages into potent anti-tumor effectors, demonstrating the power of engaging both immune system arms to fight cancer.

Indexed as

Antineoplastic AgentsNeoplasmsHumansMacrophagesAntineoplastic Agents

Identifiers

PMID34637745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.